
-
British band Muse cancels planned Istanbul gig
-
'I'll be back' vows Haaland after injury blow
-
Trump to unveil 'Liberation Day' tariffs as world braces
-
New coach Edwards adamant England can win women's cricket World Cup
-
Military confrontation 'almost inevitable' if Iran nuclear talks fail: French FM
-
US stocks advance ahead of looming Trump tariffs
-
Scramble for food aid in Myanmar city near quake epicentre
-
American Neilson Powless fools Visma to win Across Flanders
-
NATO chief says alliance with US 'there to stay'
-
Myanmar junta declares quake ceasefire as survivors plead for aid
-
American Neilson Powless fools Visma to win Around Flanders
-
Tesla first quarter sales sink amid anger over Musk politics
-
World's tiniest pacemaker is smaller than grain of rice
-
Judge dismisses corruption case against NY mayor
-
Nintendo to launch Switch 2 console on June 5
-
France Le Pen eyes 2027 vote, says swift appeal 'good news'
-
Postecoglou hopes Pochettino gets Spurs return wish
-
US, European stocks fall as looming Trump tariffs raise fears
-
Nintendo says Switch 2 console to be launched on June 5
-
France's Zemmour fined 10,000 euros over claim WWII leader 'saved' Jews
-
Le Pen ally denies planned rally a 'power play' against conviction
-
Letsile Tebogo says athletics saved him from life of crime
-
Man Utd 'on right track' despite 13th Premier League defeat: Dalot
-
Israel says expanding Gaza offensive to seize 'large areas'
-
Certain foreign firms must 'self-certify' with Trump diversity rules: US embassies
-
Deutsche Bank asset manager DWS fined 25 mn euros for 'greenwashing'
-
UK drawing up new action plan to tackle rising TB
-
Nigerian president sacks board of state oil company
-
Barca never had financial room to register Olmo: La Liga
-
Spain prosecutors to appeal ruling overturning Alves' rape conviction
-
Heathrow 'warned about power supply' days before shutdown
-
Epstein accuser Virginia Giuffre 'stable' after car crash
-
Myanmar quake survivors plead for more help
-
Greece to spend 25 bn euros in 'drastic' defence overhaul: PM
-
Maresca non-committal over Sancho's future at Chelsea
-
WHO facing $2.5-bn gap even after slashing budget: report
-
Real Madrid coach Ancelotti tells tax trial did not seek to defraud
-
Chinese tourists pine for Taiwan's return as Beijing jets surround island
-
Singapore detains teenage boy allegedly planning to kill Muslims
-
What is the 'Qatargate' scandal roiling Israel?
-
AI coming for anime but Ghibli's Miyazaki irreplaceable, son says
-
Swedish insurer drops $160 mn Tesla stake over labour rights
-
Hunger returns to Gaza as Israeli blockade forces bakeries shut
-
Rubio heads to Europe as transatlantic tensions soar
-
Like 'living in hell': Quake-hit Mandalay monastery clears away rubble
-
'Give me a break': Trump tariffs threaten Japan auto sector
-
US approves $5.58 bn fighter jet sale to Philippines
-
Tsunoda embracing pressure of Red Bull debut at home Japanese GP
-
'Outstanding' Hay shines as New Zealand seal Pakistan ODI series
-
El Salvador's Bukele flaunts 'iron fist' alliance with Trump
RIO | -0.74% | 59.79 | $ | |
CMSC | 0.43% | 22.537 | $ | |
CMSD | -0.18% | 22.78 | $ | |
SCS | 0.8% | 11.411 | $ | |
NGG | -0.09% | 65.72 | $ | |
BCC | 2.09% | 101.02 | $ | |
RBGPF | 0% | 68 | $ | |
AZN | -0.17% | 72.475 | $ | |
GSK | -1.18% | 37.43 | $ | |
RYCEF | -1.82% | 9.87 | $ | |
JRI | 0.21% | 13.007 | $ | |
BCE | -4.38% | 21.825 | $ | |
BP | -0.12% | 33.77 | $ | |
BTI | -2.76% | 39.995 | $ | |
RELX | 0.42% | 50.885 | $ | |
VOD | -1.71% | 9.114 | $ |

Onco-Innovations Extends Marketing Program
VANCOUVER, BC / ACCESS Newswire / March 25, 2025 / Onco-Innovations Limited (CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: info@mcsmarket.de; telephone: +491772481220; and website: www.mcsmarket.de) ("MCS") for the continued provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as research and analytics (the "Services"). The Services are expected to run until May 31, 2025, or until budget exhaustion. The Company has paid MCS CAD 600,000 for the extended term of Services, and no securities have been provided to MCS or its principals as compensation. The Services will be executed via digital channels, including Google Ads and native advertising.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the Company's ability to complete future research and development activities with respect thereto, and the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, the failure to complete further research and development activities in respect thereto, the failure to receive regulatory approval in respect of its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
P.A.Mendoza--AT